Edition:
India

People: Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

20.11USD
21 Jun 2019
Change (% chg)

-- (--)
Prev Close
$20.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
142,726
52-wk High
$28.84
52-wk Low
$12.36

Watts, Ryan 

Mr. Ryan Watts, Ph.D. is President, Chief Executive Officer, Co-Founder, Director of Denali Therapeutics Inc. Ryan previously served as Director of the Department of Neuroscience at Genentech, where he was employed for 11 years. During his tenure there, he led the company’s entry into neuroscience, building a department and advancing multiple programs for neurological disease from discovery to clinical testing. Ryan’s own laboratory focused on drug discovery for Alzheimer’s disease and on understanding mechanisms of neurodegeneration guided by human genetics. Ryan is also a leader in the development of improved methods for delivering therapeutic antibodies across the blood-brain barrier. He obtained his B.S. from the University of Utah and his Ph.D. in biological sciences from Stanford University.

Basic Compensation

Total Annual Compensation, USD 855,744
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 511,119
Fiscal Year Total, USD 1,366,860

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Marc Tessier-Lavignec

632,891

Ryan Watts

1,366,860

Alexander Schuth

1,076,940

Steve Krognes

1,166,560

Dana Andersen

--

Carole Ho

1,368,000
As Of  31 Dec 2017